Laurence Marton - 20 Mar 2026 Form 4 Insider Report for RenovoRx, Inc. (RNXT)

Reporting relationship: Director
Issuer ticker: RNXT
Reported as of: 20 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Mar 2026, 21:16:57 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Laurence Marton

Key filing fact

Laurence Marton filed Form 4 for RenovoRx, Inc. (RNXT) on 24 Mar 2026.

Key facts

This page summarizes Laurence Marton's Form 4 filing for RenovoRx, Inc. (RNXT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Mar 2026, 21:16.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001862192 Primary reporting owner

Marton Laurence

Relationship: Director
Address: C/O RENOVORX, INC., 2570 W EL CAMINO REAL, SUITE 320, MOUNTAIN VIEW
Signature: /s/ Laurence Marton
Signature date: 24 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNXT transaction

Common Stock

Purchase

Transaction value
Shares: +9,720
Change %
Price
Shares after: 9,720
Date: 20 Mar 2026
Ownership: Laurence Marton Rollover IRA
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNXT transaction Derivative

Warrants

Purchase

Transaction value
Shares: +4,860
Change %
Price
Shares after: 4,860
Date: 20 Mar 2026
Ownership: Laurence Marton Rollover IRA
Underlying class: Common Stock
Underlying amount: 4,860
Exercise price: $1.93
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000.

Footnote F2

The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.